Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

2 hours ago 2

Jonathan Ponciano, The Motley Fool

Sun, March 22, 2026 astatine 3:26 PM CDT 4 min read

On February 17, 2026, B Group, Inc. disclosed a caller presumption successful Structure Therapeutics (NASDAQ:GPCR), acquiring 90,000 shares successful the 4th quarter.

B Group disclosed successful a Securities and Exchange Commission (SEC) filing dated February 17, 2026, that it initiated a caller presumption successful Structure Therapeutics (NASDAQ:GPCR) by purchasing 90,000 shares. The quarter-end worth of the involvement stood astatine $6.26 million, reflecting pricing arsenic of December 31, 2025.

This caller presumption made up 4.62% of B Group’s reportable U.S. equity assets arsenic of the December 31, 2025, filing.
Top holdings aft the filing:
- NASDAQ:ADMA: $44.83 cardinal (33.2% of AUM)
- NASDAQ:CLLS: $15.88 cardinal (11.8% of AUM)
- NASDAQ:PALI: $10.57 cardinal (7.8% of AUM)
- NASDAQ:TSHA: $9.90 cardinal (7.3% of AUM)
- NASDAQ:PRAX: $9.80 cardinal (7.3% of AUM)
As of Friday, GPCR shares were priced astatine $48.59, up a staggering 132% implicit the past twelvemonth and good outperforming the S&P 500, which is alternatively up astir 15% successful the aforesaid period.

Metric

Value

Price (as of Friday)	$48.59
Market Capitalization	$3.4 billion
Net Income (TTM)	($141.2 million)

Structure Therapeutics develops oral therapeutics targeting chronic diseases, with pb candidates focused connected type-2 diabetes, obesity, pulmonary, and cardiovascular conditions.
The steadfast operates a clinical-stage biopharmaceutical concern model, generating worth done the advancement of proprietary cause candidates targeting validated G-protein-coupled receptors (GPCRs).
It targets healthcare providers and patients with unmet aesculapian needs successful chronic illness segments specified arsenic diabetes, obesity, and pulmonary fibrosis.

Structure Therapeutics is simply a clinical-stage biotechnology institution specializing successful the improvement of caller oral tiny molecule therapeutics for chronic diseases with important unmet needs. The institution leverages proprietary expertise successful targeting GPCRs to beforehand a pipeline of differentiated cause candidates, including GSBR-1290 for type-2 diabetes and obesity, and further programs for pulmonary and cardiovascular indications. With a absorption connected innovation successful oral therapeutics, Structure Therapeutics aims to code large, underserved diligent populations and found a competitory borderline successful the biopharmaceutical sector.

Structure Therapeutics sits close astatine the halfway of 1 of the astir crowded and high-stakes markets successful biotech: obesity and metabolic disease. The company’s caller information suggests it could person a existent shot. Its pb cause campaigner delivered value nonaccomplishment of much than 16% successful a mid-stage trial, putting it successful striking region of injectable therapies portion offering the convenience of an oral option. That benignant of illustration is what keeps investors engaged adjacent erstwhile the financials look messy.

And that’s somewhat the lawsuit here. The institution posted a full-year nett nonaccomplishment of astir $141 cardinal arsenic R&D spending ramped to enactment late-stage trials, a reminder that this is inactive a capital-intensive, pre-commercial story. With shares down 28% this year, the caller selloff reflects that reality, but not needfully a breached thesis. Longer-term, the upside volition hinge connected objective execution and not near-term earnings. But volatility volition apt play a relation regardless.

Read Entire Article